Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study.
Ying ChengQiming WangKai LiJianhua ShiBaohui HanLin WuGongyan ChenJianxing HeJie WangHaifeng QinXiaoling LiPublished in: Cancer innovation (2023)
Anlotinib proved to have potential CNS activity and a manageable toxicity profile in patients with SCLC and BM, significantly delaying CNS progression.
Keyphrases
- brain metastases
- small cell lung cancer
- double blind
- placebo controlled
- blood brain barrier
- acute lymphoblastic leukemia
- clinical trial
- acute myeloid leukemia
- open label
- diffuse large b cell lymphoma
- hodgkin lymphoma
- multiple myeloma
- oxidative stress
- phase iii
- phase ii
- study protocol
- human health
- risk assessment
- climate change